



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
294-262 PCT/US

SERIAL NO.
10/594,382

APPLICANT
Schwartz-Albiez, et al.

CONFIRMATION NO.
Unassigned

FILING DATE
September 26, 2006

GROUP
Unassigned

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | TRANSLATION | |
|------------------|-----------------|------------|---------|-------|-----------|-------------|----|
| | | | | | | YES | NO |
| | DE 102 45 927 A | 04/15/2004 | Germany | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|--|--|
| | | Theunissen, et al., "Long-term engrafting umbilical cord blood cells are preserved after ex vivo culture in stroma-free culture," <i>Online!</i> May 2001, http://mmserver.cjp.com/gems/blood/ABMT.10.verfaillie.pdf , pgs 599-603. |
| | | Pankaj, et al., "Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with o-sulfated heparin sulfates: Requirement for optimal binding interactions of heparin sulfate with early-acting cytokines and matrix proteins," <i>Blood</i> January 2000, 95(1):147-155. |
| | | Pankaj, et al., "Structurally specific heparin sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche," <i>Blood</i> December 1998, 92(12):4641-4651. |
| | | Lewis, et al., "Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system," <i>Blood</i> June 2001, 97(11):3441-3449. |
| | | Schubert, "Einfluss regioselektiv modifizierter Heparansulfate auf den Erhalt und die Expansion primitiver hematopoietischer Stammzelle and Vorläuferzellen," <i>Online!</i> 2004, http://doctor-schubert.de/downloads/Dissertation%20M.Schubert.pdf . |

EXAMINER

/Leon Lankford Jr./

DATE CONSIDERED

06/19/2011

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./

| | | | |
|--|--|--------------------------------------|--------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 294-262 PCT/US | SERIAL NO. 10/594,382 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | APPLICANT Schwartz-Albiez, et al. | CONFIRMATION NO. Unassigned |
| (Use several sheets if necessary) | | FILING DATE September 26, 2006 | GROUP Unassigned |

| | | |
|--|--|--|
| | | Punzel, et al., "The microenvironment of AFT024 cells maintains primitive human hematopoiesis by counteracting contact mediated inhibition of proliferation." <i>Cell Communication & Adhesion</i> , May-June 2002, 9(3):149-159. |
| | | Gupta, et al., "Artificial 'proteoglycan-like' molecules containing heparin sulfate enhance the ability of cytokines to maintain human hematopoietic stem cells in vitro," <i>Journal of Investigative Medicine</i> , 1995, 43(SUPPL2):342A. |
| | | Moore, et al., "In vitro maintenance of highly purified, transplantable hematopoietic stem cells," <i>Blood</i> , 1997, 89(12):4337-4347. |
| | | Moore, et al., "Hematopoietic Activity of a Stromal Cell Transmembrane Protein Containing Epidermal Growth Factor-Like Repeat Motifs," <i>Proceedings of the National Academy of Sciences of USA</i> , April 1997, 94:4011-4016. |
| | | Stringer, et al., "Identification of an MIP-1alpha-binding heparin sulfate oligosaccharide that supports long-term in vitro maintenance of human LTC-ICs," <i>Blood</i> , March 2003, 101(6):2243-2245. |

231578_1

| | | | |
|----------|--------------------|-----------------|------------|
| EXAMINER | /Leon Lankford Jr/ | DATE CONSIDERED | 06/19/2011 |
|----------|--------------------|-----------------|------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./